Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients

Clínica Las Condes. LIT INNOVA CORFO30 enrolled

Overview

The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Spinal Cord Injury

Interventions

Autologous Mesenchymal Stem CellsPROCEDURE

Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation

Eligibility

Sex: ALLMin age: 2 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * American Spinal Injury Association Impairment (ASIA) Scale A, B and C * Cervical (under C4), thoracic o lumbar spine lesion * Complete or Incomplete SCI * Platelet count over 100.000/ul Exclusion Criteria: * Acute SCI (less than 3 months) * Active infectious diseases * Pregnancy * Neurodegenerative diseases * Primary hematologic diseases * Coagulopathies * Hepatic dysfunction * Pregnancy

Locations (1)

Clínica Las Condes

Santiago, RM, Chile

Outcomes

Primary Outcomes

Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients

Time frame: 3 months

Secondary Outcomes

Functional improvement in muscle strength

According to motor index score

Time frame: 1 year

Functional Improvement in sphincters control

Time frame: 1 year

Functional improvement in spasticity control

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.